NASDAQ:KALV - Kalvista Pharmaceuticals Stock Price, Forecast & News

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) released its quarterly earnings results on Tuesday, December, 3rd. The specialty pharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.55) by $0.22. The specialty pharmaceutical company earned $3.92 million during the quarter, compared to the consensus estimate of $3.23 million. Kalvista Pharmaceuticals had a negative return on equity of 25.70% and a negative net margin of 182.37%. View Kalvista Pharmaceuticals' Earnings History.

Kalvista Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Kalvista Pharmaceuticals.

4 equities research analysts have issued 12 month target prices for Kalvista Pharmaceuticals' stock. Their forecasts range from $28.00 to $31.00. On average, they expect Kalvista Pharmaceuticals' share price to reach $30.00 in the next twelve months. This suggests a possible upside of 81.2% from the stock's current price. View Analyst Price Targets for Kalvista Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kalvista Pharmaceuticals.

Media coverage about KALV stock has trended somewhat negative on Monday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kalvista Pharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 877,600 shares, an increase of 11.3% from the December 31st total of 788,700 shares. Based on an average daily volume of 142,200 shares, the short-interest ratio is currently 6.2 days. Currently, 7.0% of the company's stock are sold short. View Kalvista Pharmaceuticals' Current Options Chain.

Some companies that are related to Kalvista Pharmaceuticals include IGM Biosciences (IGMS), Madrigal Pharmaceuticals (MDGL), ZEALAND PHARMA/S (ZEAL), Myovant Sciences (MYOV), Endonovo Therapeutics (ENDV), Athenex (ATNX), Rocket Pharmaceuticals (RCKT), Enanta Pharmaceuticals (ENTA), Portola Pharmaceuticals (PTLA), Opko Health (OPK), Phibro Animal Health (PAHC), Dermira (DERM), NextCure (NXTC), Karyopharm Therapeutics (KPTI) and Revance Therapeutics (RVNC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kalvista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), GALAPAGOS NV/S (GLPG), Ritter Pharmaceuticals (RTTR), BIOLINERX LTD/S (BLRX), Iovance Biotherapeutics (IOVA) and Progenics Pharmaceuticals (PGNX).

Kalvista Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include California Public Employees Retirement System (0.07%) and NEXT Financial Group Inc (0.03%). Company insiders that own Kalvista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Daniel B Soland, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View Institutional Ownership Trends for Kalvista Pharmaceuticals.

KALV stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and NEXT Financial Group Inc. Company insiders that have bought Kalvista Pharmaceuticals stock in the last two years include Albert Cha and Daniel B Soland. View Insider Buying and Selling for Kalvista Pharmaceuticals.

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KALV stock can currently be purchased for approximately $16.56.

Kalvista Pharmaceuticals has a market capitalization of $295.33 million and generates $16.13 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.View Additional Information About Kalvista Pharmaceuticals.

The official website for Kalvista Pharmaceuticals is http://www.kalvista.com/.

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]